Chamberland Frédéric, Maurina Tristan, Degano-Valmary Séverine, Spicarolen Thierry, Chaigneau Loïc
Department of Otorhinolaryngology and Head and Neck Surgery, Hospital Nord Franche-Comté , Belfort.
Department of Oncology, University Hospital Center Jean Minjoz , Besançon, France.
Rare Tumors. 2016 Oct 5;8(3):5907. doi: 10.4081/rt.2016.5907. eCollection 2016 Sep 5.
Angiosarcomas are one of the rarest subtypes of sarcomas; those are malignant vascular tumors arising from vascular endothelial cells. Occurrence of intra-oral angiosarcoma is extremely rare (0.0077% of all cancers in Europe). We present here, to our knowledge, the first case of a 83-year-old man with gingival and both palatine tonsils localization of a grade-two angiosarcoma discovered after a two months history of a painful lesion followed by hematoma and spontaneous bleeding. Chemotherapy with paclitaxel and hemostatic radiotherapy were inefficient and he died seven months after the first symptoms. It is essential to use the vascular markers, such as CD34, CD31, ERG and FLI1, for a correct histological diagnosis, which remains difficult because it displays a wide range of morphological appearances and multiple patterns may be present in the same tumor. The main prognostic factors are chronic pre-existing lymphedema and tumor size greater than five centimeters. Malignancy grade and stage classification should be provided in all cases in which this is feasible because of predictive meaning. When possible, wide surgical resection with negative margins remains the cornerstone for the treatment of localized angiosarcomas, but despite the improvement of surgical techniques the prognosis is poor with more than half of patients died within the first year. Adjuvant radiotherapy is the standard treatment of high-grade (two and three), deep lesions, regardless of size, because it improved the local recurrence-free survival. For advanced disease, if possible, metastasectomy should be considered. The first-line chemotherapy with doxorubicin or paclitaxel should be discussed compared to best supportive care according to patient comorbidities and preference.
血管肉瘤是肉瘤中最罕见的亚型之一;它们是起源于血管内皮细胞的恶性血管肿瘤。口腔内血管肉瘤的发生极为罕见(在欧洲占所有癌症的0.0077%)。据我们所知,我们在此报告首例83岁男性患者,其二级血管肉瘤位于牙龈和双侧腭扁桃体,该病例是在出现疼痛性病变、随后出现血肿和自发性出血两个月后被发现的。使用紫杉醇化疗和止血放疗均无效,患者在出现首发症状七个月后死亡。使用血管标志物,如CD34、CD31、ERG和FLI1,对于正确的组织学诊断至关重要,而这仍然很困难,因为它表现出广泛的形态学外观,并且同一肿瘤中可能存在多种模式。主要的预后因素是既往存在的慢性淋巴水肿和肿瘤大小大于5厘米。在可行的所有病例中均应提供恶性程度和分期分类,因为其具有预测意义。如果可能,切缘阴性的广泛手术切除仍然是局限性血管肉瘤治疗的基石,但尽管手术技术有所改进,预后仍然很差,超过一半的患者在第一年内死亡。辅助放疗是高级别(二级和三级)深部病变的标准治疗方法,无论大小如何,因为它可提高局部无复发生存率。对于晚期疾病,如果可能,应考虑进行转移灶切除术。应根据患者的合并症和偏好,将阿霉素或紫杉醇一线化疗与最佳支持治疗进行讨论。